Dose reduction of biologics in patients with plaque psoriasis: a review
Dose reduction (DR) of first-generation biologics for plaque psoriasis (TNF-alpha inhibitors (i) and interleukin (IL)-12/23i) has been described in a previous scoping review. The literature on the DR of the newest generation of biologics (IL-17/23i) was scarce. The current review provides a literatu...
Saved in:
Main Authors: | C. A. M. van Riel (Author), C. A. J. Michielsens (Author), M. E. van Muijen (Author), L. S. van der Schoot (Author), J. M. P. A. van den Reek (Author), E. M. G. J. de Jong (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Corrigendum: Dose reduction of biologics in patients with plaque psoriasis: a review
by: C. A. M. van Riel, et al.
Published: (2024) -
Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice
by: Selma Atalay, et al.
Published: (2021) -
Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis
by: Marloes E. van Muijen, et al.
Published: (2022) -
Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice
by: L.S. van der Schoot, et al.
Published: (2023) -
The Skin May Clear But the Arthritis Won’t Disappear: Focusing on Concomitant and New-Onset Psoriatic Arthritis in a Daily Practice Cohort of Psoriasis Patients on Biologic Therapy
by: van Muijen ME, et al.
Published: (2020)